Status of Ongoing Proceedings

For information on how to obtain public transcripts of proceedings, please contact the Registrar, Riaz Awadia, by phone at 613-288-9597 or by e-mail at Riaz.Awadia@pmprb-cepmb.gc.ca.

Dates of Upcoming Hearings or Pre-Hearing Conferences

blank
Case Event Date / Location
Procysbi - Horizon Therapeutics Canada Hearing for Motion to Bifurcate, Strike Evidence, and for the Inspection and Production of Documents January 15, 2020
Ian G. Scott Courtroom
100 Thomas-More Private
Room BRS 230

Matters before the Board

Excessive Pricing
Patented Drug Product Indication / Use Patentee Issue Date of Notice of Hearing Status
Procysbi nephropathic cystinosis Horizon Therapeutics Canada Allegations of excessive pricing February 27, 2019
Case Management
  • Board Staff’s Motion to bifurcate, strike evidence and production to be heard January 15 2020
  • Board Staff’s Statement of Allegations filed January 14 2019
Differin
Differin XP		 Acne Galderma Canada Inc. Failure to file (jurisdiction)  
  • FCA sent back matter to PMPRB’ Board Panel for RE-determination on June 28 2019
  • Written submissions RE impact of decision on Panel’s re-determination filed by both parties on July 31 2019.

Judicial Review of Board Decisions and Appeals

Patented Drug Product Indication / Use Patentee Issue Date of Notice of Application Status
Soliris Paroxysmal Nocturnal Hemoglobinuria

Atypical Hemolytic Uremic Syndrome		 Alexion Pharmaceuticals Inc. Allegations of excessive pricing January 20, 2015 Court File A-237-19 (RE T-1596-17 Board Panel’s decision of Sept 20, 2017)
  • Notice of Appeal filed by Alexion, June 21 2019
Differin Differin XP Acne Galderma Canada Inc. Failure to file (jurisdiction) February 23, 2016 Court File A-385-17
  • Decision rendered June 28 2019 sending back the file to PMPRB’s Board Panel for Re-determination
Date modified: